GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer

Abstract

Background

Breast cancer (BC) is increasingly becoming the primary reason for death in women, which sounded the alarm. Thus, finding a novel management target for BC is imminent.

Materials and Methods

The data on gene expression and clinicopathological characteristics were downloaded from The Cancer Genome Atlas (TCGA). The expression of GNPNAT1 in 40 paired breast cancer and adjacent tissues was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Univariate and Multivariate logistic regression methodology was applied to analyze the prognostic factors for lymph node metastasis (LNM). Based on the status of breast cancer-relative receptors, patients were distributed into six groups, and then the Kaplan-Meier survival analysis with a Log rank test was applied to investigate the involvement among the expression of GNPNAT1 and overall survival (OS).

Results

We found higher expression of GNPNAT1 was connected with poor survival in breast cancer by COX regulation analysis. GO, KEGG, and GSEA analysis prompted that GNPNAT1 was connected with the defense mechanism of cells, cell proliferation, and division. Immunization infiltration analysis showed that high GNPNAT1 was negatively connected with 16 immunization infiltration cell types and positively connected with four immunization infiltration cell types.

Conclusion

As a whole, our results indicated that GNPNAT1 might be a probable biomarker for diagnosis and prognosis in breast cancer.

Keywords:

• GNPNAT1
• biomarker
• breast cancer
• diagnosis
• prognosis

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author Yuying Zhou upon reasonable request.

Ethics Approval and Consent to Participate

This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, and complied with the tenets of the Declaration of Helsinki. The ethical approval code is No. 2012-57. Each patient provided written informed consent before being enrolled in the study.

Consent for Publication

The patients issued Written informed consent for the publication of this research and accompanying images. A copy of the written consent is ready for review by the Editor in Chief of this journal.

Acknowledgments

The authors would like to thank all the Department of Breast Surgery doctors at the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or all these areas; took part in drafting, revising, or critically reviewing the article; giving final approval of the version to be published; agreeing on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

Additional information

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.